Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

Micromet, Inc. announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets.

11 Jul 2011

Six new scientists to receive SWCRF grants for cancer research

This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.

1 Jul 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Convergen LifeSciences, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.

29 Jun 2011

RCSI researchers identify novel drug target for osteomyeltitis

New research from the Royal College of Surgeons in Ireland (RCSI) has identified a novel drug target for the treatment of infection in bone.

28 Jun 2011

FDA responds to EpiCept Ceplene SPA

EpiCept Corporation today announced that it has received initial written responses from the U.S. Food and Drug Administration regarding the Company's application for a Special Protocol Assessment (SPA) of the Ceplene (histamine dihydrochloride) Phase III protocol.

27 Jun 2011

EpiCept announces results of 2011 stockholders annual meeting

EpiCept Corporation announced today the results of its 2011 Annual Meeting of Stockholders held on June 14, 2011.

20 Jun 2011

Genomic study identifies MCU that regulates calcium transport into mitochondria

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Massachusetts General Hospital (MGH), the Broad Institute, and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), today announced new findings published in Nature.

20 Jun 2011

Scientists create first roadmap to understand estrogen signaling in breast cancer cells

The first roadmap to mathematical modeling of a powerful basic "decision circuit" in breast cancer has been developed and published in Nature Reviews Cancer.

18 Jun 2011

Insight into how cancer cells acquire selective survival advantage

Research led by David Litchfield of The University of Western Ontario has identified how biochemical pathways can be "rewired" in cancer cells to allow these cells to ignore signals that should normally trigger their death. It's one way that cancer cells may become resistant to therapy.

9 Jun 2011

Emphysema gene linked to lung cancer

A gene linked to emphysema also can be a factor for developing lung cancer unrelated to cigarette smoking, UT Southwestern Medical Center research indicates. Smoking was the only known risk factor previously associated with both diseases.

9 Jun 2011

$Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS$

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Telik, Inc. today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome.

8 Jun 2011

Tβ4 activates Akt survival kinase and reduces heart attack damage

RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.

7 Jun 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Enzyme Research journal publishes new peer-reviewed article involving Protandim

LifeVantage Corporation, the maker of Protandim, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim was published in the scientific journal Enzyme Research.

4 Jun 2011

Research in progress for novel protein kinase inhibitors: GEN

Biotech scientists are working on novel protein kinase inhibitors that are targeting a host of conditions ranging from atherosclerosis to neurodegenerative diseases, reports Genetic Engineering & Biotechnology News.

4 Jun 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011

Scientists uncover new therapeutic target that could prevent stress-related cell death

Scientists from the Florida campus of The Scripps Research Institute have uncovered a potentially important new therapeutic target that could prevent stress-related cell death, a characteristic of neurodegenerative diseases such as Parkinson's, as well as heart attack and stroke.

3 Jun 2011

Apoptosis News and Research

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

Six new scientists to receive SWCRF grants for cancer research

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

RCSI researchers identify novel drug target for osteomyeltitis

FDA responds to EpiCept Ceplene SPA

EpiCept announces results of 2011 stockholders annual meeting

Genomic study identifies MCU that regulates calcium transport into mitochondria

Scientists create first roadmap to understand estrogen signaling in breast cancer cells

Insight into how cancer cells acquire selective survival advantage

Emphysema gene linked to lung cancer

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Tβ4 activates Akt survival kinase and reduces heart attack damage

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Enzyme Research journal publishes new peer-reviewed article involving Protandim

Research in progress for novel protein kinase inhibitors: GEN

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Scientists uncover new therapeutic target that could prevent stress-related cell death

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News